Press releases

Thursday November 2nd, 2023
Lead Discovery Center GmbH licenses next-generation anticancer drug candidate to HLB Life Science R&D
Download PDF
Lead Discovery Center GmbH licenses next-generation anticancer drug candidate to HLB Life Science R&D
  • The new drug candidate effectively inhibits cancer cell repair by blocking RNA transcription
  • The goal is to jointly develop a new first-in-class therapeutic drug

Dortmund, Germany, and Seoul, Korea – November 2nd, 2023. HLB Life Science R&D (HLB), a leading Korean biopharmaceutical company, signed an agreement with Lead Discovery Center GmbH (LDC) to license and co-develop a next-generation anticancer drug candidate. LDC is a top-class translational research organization renowned worldwide for early-stage drug discovery. The licensed drug candidate is based on an asset largely incubated at LDC with support from the neighboring Max Planck Institute of Molecular Physiology (Dortmund, Germany).

continue

This first-in-class candidate showed anticancer efficacy in early-stage research. It especially inhibits the transcription of genes involved in the self-repair of damaged cancer cells. HLB will move the candidate into clinical development by quickly completing the preclinical phase together with LDC.

HLB announced on August 9th, 2023, the signature of the license agreement for exclusive rights worldwide of the drug candidate. LDC and its partners Max Planck Foundation, Max Planck Society and KHAN Technology Transfer Fund I (KHAN-I) will receive an upfront payment, remuneration for development and sales milestones, along with royalties based on future revenues.

Dr. Bert Klebl, CEO & CSO of LDC, says, “We are delighted to have found a strong partner in HLB Life Science R&D. HLB has the power to promote our promising and novel candidate to the next stages of development, with the aim to reach cancer patients as soon as possible. We are much looking forward to this cooperation and partnership”.

Dr. Yong Hae Han, CEO of HLB Life Science R&D and CTO of HLB Group, adds, “We have deeply discussed with LDC for a long time that both companies are very interested in researching and developing next-generation anticancer drugs. Finally, both partners have agreed to take such interests to the next level. As soon as we bring the candidate into our R&D center, we will focus all our efforts on this project, and strengthen our partnership with LDC.”

###

Contact
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany
Phone: +49 231 97 42 70 00
E-mail: pr@lead-discovery.de

###

About Lead Discovery Center GmbH

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. LDC sustains a long-term partnership with the Max Planck Society and KHAN Technology Transfer Fund I (KHAN-I), and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, invIOs, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea Lead Discovery AS, and the Helmholtz Centre for Infection Research e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information available at: www.lead-discovery.de

About HLB Life Science R&D

HLB Life Science R&D, headquartered in Seoul, South Korea, is a 100% subsidiary of HLB Life Science, which was founded in 1998 and listed on KOSDAQ in 2008, with its current market cap of 1 billion USD approximately. Both HLB Life Science and HLB Life Science R&D are owned and governed by HLB group. HLB Group has now 37 affiliates and, especially in the healthcare industry, it has established a fully integrated bio-ecosystem from research to commercialization. As a result of such ecosystem, one of the affiliates submitted an NDA to the US FDA for a first-line therapy of Hepatocellular Carcinoma (HCC). As a core of R&D within the group, HLB Life Science R&D has been developing anticancer drugs for the best cancer treatments by strengthening partnerships worldwide and exploring opportunities for synergies with its R&D capabilities.

Further information available at: http://hlbkorea.com/en/

About KHAN-I

KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with € 70 million under management. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need. The fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug development and academic spin-offs as well as pharma licensing and partnering. KHAN-I received an investment from the European Investment Fund (EIF) with the support of InnovFin Equity, and with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) under the Investment Plan for Europe. KHAN-I is also supported by Austria Wirtschaftsservice GmbH (AWS with funds provided by the Austrian Federal Ministry for Digital and Economic Affairs and the Austrian Foundation for Research, Technology, and Development), Max Planck Foundation, and Thyssen’sche Handelsgesellschaft mbH. In addition, KHAN-I sustains a preferred partnership with the Max Planck Society (Max-Planck-Gesellschaft e.V.).

Further information available at: www.khanu.de

About Max Planck Foundation

The Max Planck Foundation is a private, independent and non-profit organization with the sole purpose of providing funds for excellent, innovative and forward-looking research projects of the Max Planck Society. As additional support for scientists from the Max Planck Society the Foundation also facilitates the transfer from knowledge to application. The foundation was established in 2006 and the assets of the foundation are currently around € 650 million

About Max Planck Innovation

Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary team, MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress.

Further information at: www.max-planck-innovation.com.

###

Wednesday October 11th, 2023
LDC and JT team up for the discovery of new therapies
Download PDF
LDC and JT team up for the discovery of new therapies

Dortmund, Germany, October 11th, 2023 – The Lead Discovery Center GmbH (LDC) and Japan Tobacco Inc. (JT) have closed a collaboration agreement to discover new first-in-class therapeutic approaches, focusing around novel chemical entities for the treatment of various diseases with significant unmet medical need.

continue

Over a period of up to seven years, LDC, together with its extensive academic network, will identify high-potential projects that fit JT’s therapeutic priorities and in-licensing needs. The network includes research institutes of the Max Planck Society, other research organizations, as well as high-profile universities from all over Germany and beyond. Ideas for new therapeutic approaches will be collaboratively incubated at LDC as usual, although with additional support and expertise from JT. After achieving the proof-of-concept milestone by demonstrating in vivo efficacy for representatives of the respective new compound class, such projects will be targets for in-licensing by JT, where they will be further developed.

“We are pleased to team up with the LDC and its excellent network of academic inventors. The collaboration will enable us to identify truly novel therapeutic approaches that could make a meaningful difference in the lives of patients around the world”, says Muneaki Fujimoto, President of JT’s Pharmaceutical Business.

“We are excited to have a new industry partner on board who shares our brave ambition and the associated risks to transfer highly innovative approaches from academic research into application”, Bert Klebl, CEO and CSO of LDC, continues. “With their proven expertise in business and drug development, JT is perfectly positioned to advance early-stage projects along the value chain, and ultimately towards patients who urgently need new therapeutic options. We are looking forward to a productive and exciting collaboration.”

Academic inventors and their institutions will not only benefit from the drug discovery and development experience of both LDC and JT, but also from future commercialization revenues.

###

Contact
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany
Phone: +49 231 97 42 70 00
Mail: pr@lead-discovery.de

###

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.

LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, KinSea AS, HLB Life Science, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information at www.lead-discovery.de

About JT

JT has a pharmaceutical business that focuses on research and development, manufacturing and sales of prescription drugs.

Further information at https://www.jt.com/about/division/pharma/index.html

Tuesday September 12th, 2023
RIANA Therapeutics enters into collaboration agreement with LDC
Download PDF
RIANA Therapeutics enters into collaboration agreement with LDC

Vienna, Austria, and Dortmund, Germany – September 12th, 2023. RIANA Therapeutics, a spin-off from Vetmeduni Vienna has entered into a collaborative agreement with the Lead Discovery Center GmbH, a renowned organization specialized in translational drug discovery. This partnership marks the first important milestone on RIANA Therapeutics´ mission to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).

continue

Inhibition of PPIs is an emerging drug modality and a highly promising therapeutic approach for numerous diseases, including cancer, to overcome widespread resistance to drugs already in use and to improve treatment efficacy. Under the now-signed collaboration agreement, LDC will conduct high-throughput screening (HTS) using a diverse compound library of more than 200,000 chemical substances to identify novel PPI inhibitors targeting STAT5, a critical mediator driving the development of Acute Myeloid Leukemia (AML).

Through the strategic partnership with LDC, RIANA Therapeutics secures invaluable access to LDC’s profound expertise in the field of early drug discovery. By combining their respective strengths, RIANA Therapeutics and LDC aim to accelerate the translation of innovative discoveries into potential therapeutics, with the declared long-term goal of improving the well-being of patients on a global scale.

Anna Orlova, co-founder and CEO of RIANA Therapeutics, expressed her excitement about the collaboration: “We are thrilled to partner with LDC, a highly experienced player in drug discovery. Their expertise and capabilities will be instrumental in our efforts to develop breakthrough therapeutics for hematopoietic and other cancer types. This collaboration marks a significant milestone for RIANA Therapeutics, and we look forward to working together to advance our shared mission of improving human health.”

Peter Nussbaumer, Managing Director at LDC, added: “We are highly motivated to start the challenging discovery of inhibitors targeting oncogenic PPI interactions within this new partnership with RIANA. This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients.”

###

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.

LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information at www.lead-discovery.de

About RIANA

RIANA Therapeutics was founded in February 2023 as a spin-off of Vetmeduni in Vienna by Anna Orlova, Richard Moriggl, and Oliver Szolar. The technological foundation is based on a proprietary platform technology for the discovery of compounds that target cancer-promoting protein-protein interactions (PPI), enabling a reliable search for inhibitors that block the formation of specific oncogenic PPIs. Building upon this novel proprietary technology, the team led by Orlova is working on developing new compounds specifically targeting AML, as well as other blood cancers and certain types of solid tumors.

Further information at www.rianatx.com

###

Contact
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany
Phone: +49 231 97 42 70 00
Mail: pr@lead-discovery.de

Wednesday February 8th, 2023
Norwegian Start-up KinSea to Exploit the Potential of Marine Bioactives for the Treatment of Cancer and other Diseases
Download PDF
Norwegian Start-up KinSea to Exploit the Potential of Marine Bioactives for the Treatment of Cancer and other Diseases
  • Launched by UiT The Arctic University of Norway (UiT), University of Bergen (UiB), Norinnova, and Lead Discovery Center (LDC)
  • Lead program with outstanding in vivo efficacy as pan-mutant FLT3 kinase inhibitor in AML, even against hard-to-treat, drug-induced and drug-resistant mutations
  • Diversified drug discovery pipeline to be established based on the partners’ unique access to bioactives from the Arctic Ocean and premier drug discovery expertise
  • Financing secured by KHAN Technology Transfer Fund I
continue

February 8th, 2023, Tromsø and Bergen, Norway, Dortmund, Germany. Norinnova, UiT The Arctic University of Norway (UiT), the University of Bergen (UiB) and the Lead Discovery Center GmbH (LDC), launched a new spin-out company, KinSea Lead Discovery AS (KinSea), to further develop an FLT3 kinase inhibitor program at lead status based on unique chemistry from marine sources towards (pre)clinical development. In addition, KinSea in a collaboration with UiT shall continue to comprehensively exploit the potential of marine bioactives for the treatment of human diseases. Seed financing is initially secured through a convertible loan from KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), an early-stage life sciences venture fund based in Germany, with the purpose to
expand the investor syndicate.

The company is based in Tromsø and will initially focus on its pan-mutant FMS-like tyrosine kinase 3 (FLT3) inhibitor program which has strong potential to overcome the limitations of currently available first- and second-generation FLT3 inhibitors for the treatment of acute myeloid leukemia (AML) as well as other hematologic tumors. It is founded on a proprietary scaffold based on a natural product from the Arctic Ocean that has been discovered and further developed by the founding partners. Results from in vivo proof-of-concept studies in an animal model of AML suggest superior properties over existing FLT3 inhibitors, including broad activity against known drug-induced and drug-resistant FLT3 mutations, improved selectivity, and outstanding in vivo potency. The project has been developed in collaboration between UiT, UiB, and LDC and has been funded by the Norwegian Research Council and the regional biotech program MABIT.

‘For AML patients this may translate into safer, more effective and entirely new treatment options, where other drugs fail. It is a great opportunity to exploit the potential of this program for the benefit of patients,’ says Jeanette Hammer Andersen, CEO of KinSea. ‘We are excited to continue our longstanding collaboration on marine bioprospecting and to take our FLT3 inhibitors through the next steps in the drug discovery pipeline,’ adds Bengt Erik Haug, CSO of KinSea.

Using the proceeds of the seed financing, KinSea plans to mature its lead program into a preclinical candidate ready for advanced preclinical and clinical development by licensing partners. In addition, the company will seek to use UiT’s marine bioactives repository to gradually expand its drug discovery pipeline and become a sustainable source of high-potential drug candidates based on novel scaffolds from the Arctic Ocean.

‘We are convinced there are many more treasures hidden in the Arctic Ocean that could help solve some of the most pressing challenges in human health,’ adds Bert Klebl, CEO & CSO of LDC. ‘With its premier access to marine bioactives and the distinguished drug discovery expertise of its partners, KinSea is perfectly positioned to unlock this potential.’

Dag Rune Olsen, UiT´s director: Through our research effort on marine bioprospecting, highly motivated scientists, and the longstanding fruitful collaboration with the LDC, we have created the basis for this spin-out company. It is important for UiT to contribute to new business and value creation through innovation based on excellent research’.

‘The faculty of Mathematics and Natural Sciences sees the KinSea start-up as a very positive outcome of the longstanding high-level research that is being conducted at the faculty. Providing new knowledge and facilitating for innovation based on research is at the heart of the faculty´s mission. Together with a skilled team of partners we aim to fulfill the translation from basic research to a socially beneficial innovation project’, states Gunn Mangerud, UiB´s Dean of the Faculty of Mathematics and Natural Sciences.

###

About UiT
UiT The Arctic University of Norway (UiT) is the northernmost university of the world. Its location on the edge of the Arctic implies a mission. The Arctic is of increasing global importance. Climate change, the exploitation of Arctic resources and environmental threats are topics of great public concern, which UiT situated in all of Northern Norway take special interest in. At UiT The Arctic University of Norway we explore global issues from a close-up perspective.

About UiB
The University of Bergen (UiB) is an internationally recognised research university. Academic diversity and high quality are fundamental for us, as we aim is to develop knowledge that shapes society. UiB is the most cited university in Norway and we are among the very best in the world at interacting and collaborating internationally, and with actors outside the university. Situated in the Ocean City of Bergen, UiB has been assigned a leading role on the work with Sustainable Development Goal 14 Life Below Water.

About Norinnova
Norinnova is one of Northern Norway’s most competent and experienced agencies for research commercialization. Norinnova connects researchers, start-up environments, companies and commercial actors to develop and utilize the region’s innovation power. For more than 30 years, Norinnova has worked closely with researchers and leading research communities in Northern Norway to harness the power of innovation in the north. This collaboration has contributed to the creation of brand-new businesses and has reinforced existing companies through new products and services. Norinnova secures rights, helps provide funding, investigates market potential, finds relevant partners, and contributes so that the scientists can get their product or service to the market.
Further information at
www.norinnova.no

About LDC
Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. LDC sustains a long-term partnership with the Max Planck Society and KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Roche, InvIOs, e.g. In addition, LDC also works with leading translational drug  discovery centers and with various investors to provide its assets for company creation.
Further information at
www.lead-discovery.de


About KHAN-I
KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with €70 million under management. Our mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need. The fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug development and academic spin-offs as well as pharma licensing and partnering. KHAN-I received an investment from the European Investment Fund (EIF) with the support of InnovFin Equity, and with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) under the Investment Plan for Europe. KHANI is also supported by Austria Wirtschaftsservice GmbH (AWS with funds provided by the Austrian
Federal Ministry for Digital and Economic Affairs and the Austrian Foundation for Research, Technology, and Development), Max Planck Foundation, and Thyssen’sche Handelsgesellschaft mbH. In addition, KHAN-I sustains a preferred partnership with the Max-Planck Society (Max-Planck Gesellschaft e.V.).
Further information at
www.khanu.de

###

Contact
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany
Phone: +49 231 97 42 70 00
Mail: pr@lead-discovery.de

Wednesday September 28th, 2022
Start-up CalTIC secures up to EUR 3 million in seed financing to develop a new class of drugs targeting TRPC channels
Download PDF

Start-up CalTIC secures up to EUR 3 million in seed financing to develop a new class of drugs targeting TRPC channels

Dortmund, Germany, and Leeds, UK– September 28th, 2022. The KHAN Technology Transfer Fund I (KHAN-I) has committed up to EUR 3 million in milestone-dependent payments to CalTIC, a Dortmund based start-up, for the discovery of a new class of drugs.

continue

The start-up builds on a long-term collaboration between the Lead Discovery Center GmbH (LDC), the Max Planck Institute of Molecular Physiology (MPI-MP) and the University of Leeds (UoL), which resulted in the validation of transient receptor potential canonical (TRPC) channel inhibition as a promising new approach for the treatment of widespread conditions, including metabolic diseases, obesity, and heart hypertrophy. Using the proceeds, the founding partners will continue their collaboration to advance their results to preclinical stage. CalTIC’s stakeholders are UoL, LDC, the Max Planck Society (MPG), Prof. Marc Freichel at the Institute of Pharmacology at Heidelberg University, and KHAN-I.

The inhibition of TRPC channels presents an entirely new approach to treating metabolic and heart disease,” says Bert Klebl, CEO & CSO of LDC. “It holds significant potential for patients, and we are very much looking forward to continuing our collaboration with this group of excellent scientists and clinicians to translate it into practice.”

CalTIC’s TRPC inhibitors block binding sites that were originally discovered by Prof. David J. Beech (UoL) and Prof. Herbert Waldmann (MPI-MP) as targets of Englerin A. Results from various in vivo models support both the potency and safety of the approach of the newly developed TRPC channel inhibitors in metabolic and heart disease.

We are delighted that KHAN-I has placed great confidence in CalTIC,” says Klaus Dinkel, CEO of CalTIC, “With KHAN’s investment and our partners’ continued commitment, we are perfectly positioned to exploit the exciting project.”

For drugs that inhibit receptors, we refer to receptor subtypes, such as beta-adrenoceptor-blocking drugs and so on. But for calcium channels, we refer to calcium-channel blockers as if there is only one type of calcium channel, yet we now know this isn’t the case – there are many. Our CalTIC therapeutic innovation partnership will target some of these new calcium channels. It’s a hugely exciting moment to see the potential for new medicines after years of effort getting to this point,” states Prof. David Beech, UoL School of Medicine.

###

 

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. LDC sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co.KG and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Roche, Apeiron, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information at: www.lead-discovery.de

About KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I)

KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) is an early-stage life sciences venture fund with € 70 million under management. Our mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need. The fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug development, academic spin-offs as well as pharma licensing and partnering. 

KHAN-I received an investment from the European Investment Fund (EIF) with support of InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) under the Investment Plan for Europe. KHAN-I is also supported by Austria Wirtschaftsservice GmbH (AWS with funds provided by the Austrian Federal Ministry for Digital and Economic Affairs and the Austrian Foundation for Research, Technology and Development), Max Planck Foundation and Thyssen’sche Handelsgesellschaft mbH. 

For more information visit www.khanu.de

 

About University of Leeds

The University of Leeds is one of the largest higher education institutions in the UK, with more than 38.000 students from more than 150 different countries, and a member of the Russell Group of research-intensive universities. The University plays a significant role in the Turing, Rosalind Franklin and Royce Institutes. We are a top ten university for research and impact power in the UK, according to the 2014 Research Excellence Framework, and are in the top 100 of the QS World University Rankings 2020. The University was awarded a Gold rating by the Government’s Teaching Excellence Framework in 2017, recognising its ‘consistently outstanding’ teaching and learning provision. Twenty-six of our academics have been awarded National Teaching Fellowships – more than any other institution in England, Northern Ireland and Wales – reflecting the excellence of our teaching.

Further information at: www.leeds.ac.uk

 

 

###

Contact:
Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany
pr@lead-discovery.de

###

Wednesday September 7th, 2022
QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing
Download PDF

QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders

Dortmund, September 7th, 2022 — Qli5 Therapeutics GmbH (QLi5), a German-Korean joint venture developing a new class of proteasome inhibitors, has closed a EUR 10 million series A financing round with an international consortium of investors including SV Investment (Korea), KHAN Technology Transfer Fund I (Germany), Atinum Investment (Korea) and DAOL Investment (former KTB, Korea).

continue

QLi5 will use the proceeds to advance its pipeline of highly-differentiated proteasome inhibitors to the start of clinical trials addressing various indications. The proteasome functions as cellular ‘garbage processing facility’ eliminating misfolded, damaged or expired proteins. It is therefore critical to cell survival and presents a compelling target for the treatment of multiple conditions that involve an overproduction of non-functional proteins, including cancer, inflammation, and autoimmune diseases.
 
Based on the leading proteasome expertise of Nobel laureate and company co-founder Prof. Robert Huber and a multi-year collaboration between his lab at the Max Planck Institute for Biochemistry and the Lead Discovery Center (LDC), QLi5 has established a versatile platform for the design of proteasome inhibitors with outstanding selectivity, unique non-covalent binding characteristics and favourable pharmacodynamic properties.
 
“This new class of proteasome inhibitors has significant advantages over first-generation approaches and opens a wide field of therapeutic applications. We are very much impressed with both, the platform and the progress made so far”, Representative of SV Investment says.
 
“QLi5 demonstrates what can be achieved when excellent science meets with professional drug discovery and development expertise”, adds Kiyean Nam, CEO and CSO of Qurient, co-founder of QLi5 and long-term strategic partner of the Max-Planck-Society and the LDC.
 
“We are glad to see the program advance so rapidly and efficiently. With the financing and added management expertise it is well on track to deliver on its promise for many patients who currently lack sufficient treatment options”, says Bert Klebl, CEO of LDC.
 
“The commitment of this renowned group of investors highlights the exceptional potential of QLi5’s proteasome programs. I am looking forward to being part of this team of brilliant scientists and drug developers. Together, we are perfectly set to bringing the approach full fruition, medically and commercially”, says Martin Huber, CEO of QLi5.
 
“The current financing round is straightforwardly enabling new opportunities for treating patients with cancer, inflammation and autoimmune diseases. We are perfectly satisfied, that the groundbreaking work from the Max Planck Institute for Biochemistry, put into experienced hands in industry, lays the foundation for this promising endeavour”, explains Dieter Link, licensing and patent manager at Max Planck Innovation.

###

>> Contact

QLi5 Therapeutics GmbH
Martin Huber
Otto-Hahn-Straße 15
D–44227 Dortmund
Tel.: +49 177 8524152
Mail: huber@QLi5tx.com

###

About QLi5

QLi5 was founded in 2019 as a joint venture of Qurient Co. Ltd, Korea, Max Planck Society (MPG), Germany, Lead Discovery Center (LDC), Germany, Nobel laureate Prof. Robert Huber, emeritus director of the Max Planck Institute for Biochemistry, Germany. The company has established a proprietary platform for the development of proteasome inhibitors with high selectivity and unique, non-covalent binding properties. Using the proceeds of a EUR 10 million series A financing in 2022, the company is advancing its pipeline and preparing clinical trials in various indications including cancer, inflammation and autoimmune diseases.
The key role of the proteasome is the elimination of misfolded, damaged or expired proteins. The principle of proteasome inhibition was discovered in many years of basic research by the Max Planck Society. The extremely complex multi-subunit protein 3D-structure of the constitutive and immuno-proteasome was resolved by Prof. Huber’s lab. This solid structural understanding enabled the development of novel chemical series of proteasome inhibitors with a wide range of selectivity.

Further information at: www.qli5tx.com

About SV Investment, Korea

SV Investment is a venture capital & private equity firm headquartered in Seoul, Korea, with offices located in Boston, Shanghai, Shenzhen and Jakarta. Founded in 2006, we’ve invested in more than 220 companies, and made 48 successful IPOs. We invest in sectors with high growth potentials, mainly TMT, consumer & entertainment, healthcare and advanced manufacturing. As a strategic value creator, we prefer to lead the investment round and form a sound partnership with our investee companies, support the company in globalization, business development, strategy, HR etc.

About KHAN Technology Transfer Fund I GmbH & Co. KG (KHAN-I)

KHAN-I is a limited partnership under German law with the European Investment Fund (EIF), Max Planck Foundation (MPF), Austria Wirtschaftsservice GmbH (AWS), Thyssen’sche Handelsgesellschaft, and KHAN-I Vermögensverwaltung GmbH & Co. KG as non-managing limited partners and Khanu Management GmbH (KHANU) as general partner and fund manager. The purpose of KHAN-I is to invest in innovative drug discovery projects and spin-out companies, primarily originating from academic sources, at the discovery, pre-clinical and clinical development stage for human healthcare and, opportunistically, veterinary care as well as to commercialise the results and products of the investments and, thus, to participate, directly or indirectly, in future proceeds.

About Atinum Investment, Korea

Atinum Investment is a top-notch Venture Capital firm established in 1988. Our investment philosophy revolves around the idea of finding the right intrinsic value of venture companies. With the insight of the various industry specialists at hand at Atinum Investment, we have comprehensive expertise in unearthing companies with high growth potential. Atinum manages Assets of more than US$1 billion in 26 funds and has invested in 400+ companies since its company set up in 1988.

About DAOL Investment (former KTB), Korea

DAOL (former KTB) was founded in 1981 as the first Venture Capital firm in Korea. Since then, DAOL has successfully managed over US$3 billion in venture and growth capital funds. We have learned how to uncover value for our portfolio companies and build lasting relationships. Throughout DAOL’s over 40 years of history, more than 250 portfolio companies of DAOL have gone public in Korea and abroad, accounting for over 10% of Korean IPOs. DAOL has offices in Seoul, Shanghai and Silicon Valley.

About Qurient, Co. Ltd.

Qurient, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for oncology and inflammatory diseases from discovery to human proof-of-concept through a virtual R&D project management platform. Qurient’s pipeline includes multiple drug candidates in preclinical to phase 2 clinical development.

For more info, please visit www.qurient.com.

About Lead Discovery Center GmbH (LDC)

LDC was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential. LDC sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co.KG and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, Roche, Apeiron, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information at: www.lead-discovery.de

About Max Planck Innovation

Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary, team MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress.

Further information at: www.max-planck-innovation.de

Wednesday February 9th, 2022
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy
Download PDF

Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy

Phase 1/2 clinical study in patients with advanced solid tumor expected to start in Q2/2022

Dortmund, Germany, and Seongnam-Si, Korea, February 9th, 2022 – Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company, announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q901, a small molecule oncology drug candidate targeting cyclin dependent kinase 7 (CDK7).

continue

The company plans to enroll up to 70 patients with advanced solid tumors in a Phase 1/2 clinical study taking place in the United States. The goal of the study will be to determine the maximum tolerated dose, dose-limiting toxicities, and the recommended Phase 2 dose of Q901.

“IND clearance for Q901 is an important step forward in developing this novel drug candidate that may provide a new alternative treatment to patients with relapsed or refractory malignancies,” says Kiyean Nam, CEO of Qurient. “We look forward to initiating the clinical study for Q901 and presenting additional nonclinical efficacy data of Q901 in various cancer models at an upcoming scientific meeting.”
 
Q901 is a highly selective CDK7 inhibitor that has been shown in in vitro studies to only inhibit CDK7 in the human kinome. CDK7 is a master regulator of cell cycle checkpoints and an essential component of the transcription machinery. Additional data from preclinical studies has demonstrated that selective inhibition of CDK7 specifically kills cancer cells with aberrant cell division cycle or transcriptional regulation. Nonclinical pharmacology studies of Q901 have demonstrated that the selective inhibition of CDK7 exerts tumor growth inhibition in a number of murine cell-derived and patient-derived xenograft models, including breast, ovarian, prostate, pancreatic, small-cell lung, and colorectal cancers.
 
Qurient licensed the CDK7 inhibitor program at lead stage from Lead Discovery Center (LDC) and the Max Planck Society and further optimized the program, completed the IND-enabling studies, and submitted the IND application.
 
“We are thrilled about the second CDK-selective inhibitor from the LDC pipeline to reach cancer patients. The nomination of Q901 for clinical development emphasizes the translational competence of LDC and represents an extremely important milestone,” adds Bert Klebl, CEO and CSO of the LDC. “Starting out with an early-stage and BMBF grant funded academic collaboration with two academic partners, and strongly supported by additional financing from the Max Planck Foundation, LDC has launched this journey to identify and generate mono-specific CDK7 inhibitors. After an initial animal proof-of-concept, the CDK7 assets were licensed to our strategic collaboration partner, Qurient. We respectfully appreciate our ongoing partnership with Qurient, who are now moving the second joint program, after Q702, forward to clinical trials. While licensing these projects and jointly starting the spin-off, QLi5, we have since built a sustainable and strong partnership with Qurient, with more to come, focusing on the translation of innovative biology and drug discovery programs from LDC’s academic network.”
 
“Qurient has proven to be the ideal partner for this project, and we are more than happy about the results of this strategic partnership,” says Jörn Erselius, Managing Director at Max Planck Innovation GmbH.
 
The CDK7 inhibitor project and other projects have been supported in part by private sponsors and charities, especially Max Planck Foundation, which supports many Max Planck research projects and researchers, including the most recent Nobel Laureates at Max Planck. 
 

# # #

>> Contact
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

# # #

About LDC
Lead Discovery Center GmbH was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The Lead Discovery Center takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the Lead Discovery Center is building a strong and growing portfolio of small molecule leads with exceptional medical and commercial potential. The Lead Discovery Center sustains a long-term partnership with the Max Planck Society, KHAN-I GmbH & Co.KG and has formed alliances with Qurient, AstraZeneca, Apeiron, Bayer, Boehringer Ingelheim, Centessa, Merck KGaA, Daiichi Sankyo, Jemincare, Novo Nordisk e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation. Further information at: www.lead-discovery.de.

About Qurient

Qurient is a clinical-stage biopharmaceutical company listed in Korea Exchange (KRX 115180). Qurient mainly focuses on development of novel therapeutics from discovery to human proof of concept stages through virtual R&D project management platform. Qurient currently has three programs in clinical development: Q301, a topical leukotriene inhibitor for atopic dermatitis, completed Phase 2b study; Telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for tuberculosis, completed Phase 2 study; and Q702, under Phase 1/2 study. A subsidiary of Qurient, QLi5 is developing immunoproteasome inhibitors targeting multiple Myeloma and diverse other indications. For more info, please visit www.qurient.com.
 
About Max Planck Innovation
Max Planck Innovation (MI) is responsible for the technology transfer of the Max Planck Society and, as such, the link between industry and basic research. With an interdisciplinary, team MI advises and supports scientists at Max Planck Institutes in evaluating their inventions, filing patents and founding companies. MI offers industry unique access to the innovations of the Max Planck Institutes. Thus, MI performs an important task: the transfer of basic research results into products that contribute to economic and social progress. Further information at: www.max-planck-innovation.com.